O bstructive sleep apnea (OSA) is associated with an elevated risk of cardiovascular disease.
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(but not compared with WL alone) in reducing serum C-reactive protein levels, insulin resistance, and dyslipidemia. These results indicated that obesity (but not OSA) was the primary causal factor in these abnormalities. However, a secondary analysis of BP changes demonstrated that systolic BP (SBP) was reduced in all study arms. Although no significant between-group differences were present in intention-to-treat (ITT) analyses, a greater reduction in the combined intervention group than either of the monotherapy groups was observed in per-protocol analyses that included subjects compliant with therapy, suggesting that both OSA and obesity independently contribute to hypertension.
In general, BP is determined by a steady component (mean arterial pressure [MAP] ), which is strongly dependent on microvascular resistance, and a pulsatile component, which is strongly dependent on conduit artery properties. The pulsatile component, often represented by pulse pressure, is increasingly recognized as an important determinant of cardiovascular risk. However, pulse pressure (and systolic pressure) is different in the arm compared with the central aorta. 13 Central aortic pulse pressure, in particular, is impacted by wave reflections from the peripheral arterial tree returning to the heart. [14] [15] [16] [17] Central pulsatile hemodynamics and arterial stiffness are independent predictors of cardiovascular risk. 13, [18] [19] [20] Whereas arterial stiffness has been linked to OSA in multiple observational studies, [21] [22] [23] [24] [25] little experimental data are available on the effect of CPAP, WL, or both, on either central hemodynamics or arterial stiffness.
In this study, we report on the results of an ancillary study of the COSA trial, in which changes in central BP and carotidfemoral pulse wave velocity (CF-PWV) were assessed, in response to randomized CPAP therapy, WL therapy, or both.
Methods

Study Design
This was a randomized, parallel-group, 3-armed trial comparing the effects of CPAP, WL, or both (CPAP plus WL) among subjects with (1) obesity, defined as body mass index ≥30 kg/m 2 ; (2) moderate-tosevere OSA, defined as the presence of an apnea-hypopnea index ≥15 events/h; and 3) serum C-reactive protein level ≥1 mg/dL. The study design, along with the detailed inclusion and exclusion criteria, has been described previously. 12 In brief, study participants were initially screened with a home-based sleep monitor. For those with apnea-hypopnea index ≥10 events/h, this was followed by diagnostic polysomnography. Subjects with apnea-hypopnea index ≥15 on polysomnography were randomized using a permuted block design with stratification according to enrollment site (Hospital of University of Pennsylvania and VA Medical Center), sex, and statin use.
This ancillary study was initiated with funding awarded by the American Heart Association several months after the primary National Heart, Lung and Blood Institute-funded trial was initiated. Once the ancillary trial was implemented, however, all subjects in the main trial were also enrolled in this ancillary study.
Interventions
The primary interventions for this trial were CPAP therapy and WL, either alone or in combination. For subjects in the CPAP-only and the combined intervention arms, CPAP was initially calibrated in the laboratory followed by continued therapy with either a fixed pressure or an auto-adjusting CPAP. Adherence was monitored weekly with the help of a router attached to the device. Subjects in the WL and the combined intervention arm received individual weekly counseling sessions targeted toward a goal caloric intake and progressively increasing durations of unsupervised exercise. Cognitive behavioral strategies including self-monitoring, goal setting, and problem-solving were used to promote compliance to WL recommendations.
Outcome Assessments
Assessments were performed at baseline, 8 weeks, and 24 weeks after the initiation of therapy and are detailed further in the onlineonly Data Supplement. Central pressure waveforms were obtained with applanation tonometry of the carotid artery, using a highfidelity Millar tonometer (Millar Instruments, Houston, TX) and a SphygmoCor PWV Vx System (Atcor Medical; Sydney, Australia). We recorded radial artery waveforms from the wrist of the dominant arm. Radial waveforms were calibrated according to sphygmomanometric systolic and diastolic pressures measured in the brachial artery. MAP was obtained via integration of the radial pressure waveform. Carotid pressure waveforms were calibrated using radial MAP and diastolic BP, which varies minimally along the arterial tree. Because some amplification of the pulse pressure occurs between the aorta and the carotid artery, we performed a second set of sensitivity analyses, in which we obtained central (aortic) pressures using a generalized transfer function applied to the radial pressure waveform, as previously described. 26, 27 CF-PWV, considered the noninvasive gold standard index of large artery stiffness, 19, 28 was measured using the SphygmoCor system. In brief, carotid-to-femoral transit time (ΔT) was computed from the foot-to-foot time difference between sequentially acquired carotid and femoral waveforms, using the intersecting tangents method, and the QRS complex of the ECG as a fiducial point. The distance between the sternal notch and the carotid artery was subtracted from the distance between the sternal notch and the femoral artery, to estimate the path length (L), and PWV was computed as L/ΔT. Distance measurements were performed using a rigid caliper, to avoid an artificial effect of obesity in distance measurements that can occur with flexible tape measures.
Statistical Analysis
Continuous data are described as mean±SD or counts (percentages) as appropriate. Statistical analyses were performed (1) on a primary modified ITT population, defined as all participants who were randomized to a study group and had at least 1 outcome assessment observation after randomization, and (2) in a per-protocol analysis restricted to participants who met prespecified minimum requirements for WL (at least 5% of baseline weight) and adherence to CPAP therapy (use for an average of at least 4 hours per night on at least 70% of the total number of nights). The ITT analysis best represents the expected therapeutic effects of our interventions as implemented in the trial. The per-protocol analysis is most informative about causal relationships between OSA or obesity on the end points; this is based on the fact that any incremental benefit of effective combination therapy (WL combined with effective CPAP treatment), relative to effective CPAP alone, must be because of the effects of obesity that are independent of the effects of OSA. Conversely, any incremental benefit of effective combination therapy, when compared with effective WL alone, must be because of the effects of OSA that are independent of the effects of obesity. 12 The effects of the interventions on end points were analyzed with the use of general linear mixed models, with all measurements available used to estimate intervention effects at 24 weeks. Estimates are presented as mean (95% confidence interval [CI]). Analyses were performed with SAS software, version 9.2 (SAS Institute).
Results
Study Participants
Of the 181 total participants who underwent randomization in the parent trial, 139 participated were included in this substudy (CPAP: n=45, WL: n=48, CPAP+WL: n=46). Seventyone participants were found to meet adherence criteria and were included in the per-protocol analysis. A flowchart of study participants at each stage is shown in Figure S1 in the online-only Data Supplement.
Baseline characteristics of the tonometry subsample of study participants when compared with those without tonometry measurements are shown in Table 1 . The mean age of the participants was 49.4±11.2 years, and 42.3% of the subjects were female. The age and sex distribution of the substudy population was not significantly different from those not included in the substudy. However, there was a significantly higher proportion of Whites and lower proportion of Blacks among subjects enrolled in this substudy. Diastolic BP and heart rate were significantly but slightly lower among subjects enrolled in this substudy. There were no other significant differences between the 2 populations with respect to tobacco use, alcohol consumption, or use of antihypertensive agents or statins.
General baseline characteristics of the tonometry subsample of study participants randomized to WL, CPAP, or both are shown in Table 2 . No significant differences were observed in various characteristics, except for a slightly greater body mass index at baseline among subjects randomized to CPAP. Changes in body weight, body mass index, and peripheral BP are summarized in Table S1 in the online-only Data Supplement.
Systolic Blood Pressure
In ITT analyses, central SBP assessed with carotid arterial tonometry was reduced significantly only in the combination arm (−7.4 mm Hg; 95% CI, −12.5 to −2.4 mm Hg; P=0.004), 
Mean and Diastolic Blood Pressure
Pulse Pressure
In the ITT analyses, the reduction in central (carotid) pulse pressure ( Figure 2A 
Pulse Pressure Amplification
Pulse pressure amplification, assessed as the ratio of carotid over brachial artery pressure, did not significantly change from baseline in any of the 3 arms in ITT analysis ( Figure 3A 
Augmentation Index
The central augmentation index did not significantly change from baseline in any of the 3 arms in ITT analysis ( Figure 3C ; CPAP: 2.5; 95% CI, −4.7 to 9.7; P=0.48; WL: −5.7; 95% CI, −13.5 to 2.0; P=0.14; CPAP+WL: 2.1; 95% CI, −5.3 to 9.5; P=0.58). Similar findings were noted in per-protocol analysis ( Figure 3D 
Carotid-Femoral Pulse Wave Velocity
In ITT analyses, no significant changes in CF-PWV were observed in any of the 3 study arms (CPAP: −0.13 m/s; 95% CI, −0.65 to 0.39; WL: −0.04 m/s; 95% CI, −0.55 to 0.47; WL+CPAP: 0.05 m/s; 95% CI, −0.45 to 0.54; Figure 4A ). There were no significant differences in the change in CF-PWV between the groups (P value for all pairwise comparisons >0.05). In prespecified per-protocol analyses restricted to subjects who complied with randomized therapy, these results were not appreciably different ( Figure 4B ).
The change in MAP induced by the intervention was a significant predictor of the change in CF-PWV (Pearson  R=0.31; P=0.008) . Similarly, the change in heart rate was weakly related to the change in CF-PWV (Pearson R=0.23; P=0.027). After adjustment for MAP and heart rate, no significant changes in CF-PWV were observed in either group, without significant between-group differences, in either ITT analyses or prespecified analyses in subjects who met compliance criteria.
Discussion
In this study, we found that, in obese individuals with moderate-to-severe OSA, combination therapy with WL and CPAP (but not CPAP or WL monotherapy) reduced central SBP. These results were consistently found when either carotid tonometry (without a transfer function) or radial tonometry (with the use of a generalized transfer function) was used. However, the reduction in central SBP was largely the result of a larger reduction in MAP in the combination arm because central pulse pressure or large artery stiffness (measured as CF-PWV) was not significantly reduced in either arm in ITT analyses. Among participants who complied with therapy, a significant reduction in central pulse pressure in the CPAPonly arm was observed, which was not seen in either the WL arm or the combined intervention arm. Overall, however, pulse pressure amplification was not significantly changed by WL, CPAP, or combination therapy, suggesting that brachial systolic (and pulse) pressure remains a good surrogate of central pulse pressure changes in response to these interventions.
Previous randomized controlled trials have studied the effect of CPAP therapy on BP in comparison to splinting devices, sham CPAP, or supplemental nasal oxygen, with variable results. Whereas most trials in patients with resistant hypertension have shown a significant improvement with CPAP, trials in normotensive subjects or those with nonresistant hypertension, similar to our population, have shown conflicting results. [3] [4] [5] [6] 11, [29] [30] [31] However, the negative results have largely been from trials reporting effects of CPAP in subjects with mild OSA 30 or shorter durations of therapy, 29, 31 and recent meta-analyses of randomized controlled trial data have confirmed a small but statistically significant reduction in BP with CPAP therapy. 32, 33 In our study, we noted a significant reduction in MAP with CPAP in both ITT and per-protocol analyses, consistent with the notion that sleep apnea leads to hypertension, and that CPAP monotherapy can achieve a small BP effect. Furthermore, because the combined CPAP and the WL intervention achieved a significantly higher reduction in MAP compared with CPAP alone, it follows that both obesity and OSA have independent effects on BP and concurrent treatment of both achieves a larger BP reduction. This is in concordance with the results of the primary study measuring peripheral pressures, where compliant subjects in all 3 arms achieved significant MAP reduction with the highest effect in the combination intervention arm. 12 We report, for the first time, the effect of CPAP, WL, or the combination of CPAP and WL on central hemodynamics and large artery stiffness. We found a significant reduction in central systolic pressure only in the combined CPAP+WL arm. Interestingly, we also observed a reduction in central pulse pressure in compliant subjects randomized to CPAP therapy. This finding, although interesting, should be interpreted with caution. First, this is a finding in a subsample of individuals enrolled in the parent trial, who had both available tonometry measurements (for estimation of central pressures) and adequate compliance to therapy. Furthermore, the analyses overall suggest that pulse pressure amplification does not change with CPAP, WL, or the combination, suggesting that peripheral pulse pressure is an adequate surrogate of central pulse pressure with regards to the response to these interventions. Of note, in the parent trial, pulse pressure was reduced in the combined intervention group in the ITT analysis, and in per-protocol analyses including compliant subjects, it was reduced in the combined CPAP+WL and the WL monotherapy arm.
OSA has also been linked to increased arterial stiffness and a recent meta-analysis summarizing 18 studies confirmed this association. 25 Evidence from prior studies on the impact of CPAP therapy in reducing arterial stiffness is less concrete with only a few randomized controlled trials evaluating this effect, 7, [34] [35] [36] of which 3 studied the gold standard measure of large artery stiffness, CF-PWV. 7, 35, 36 Contrary to our results, Drager et al 7 and Litvin et al 36 described striking reductions in CF-PWV with 4 months and 3 weeks of CPAP therapy, respectively, whereas Jones et al 24 did not find a significant difference in CF-PWV with 12 weeks of CPAP therapy in patients with mild OSA. In our study, we did not observe any significant reduction in arterial stiffness with CPAP, WL, or both interventions combined even in subjects who demonstrated compliance with therapy. Of note, both the reduction in MAP and heart rate were significant predictors of the change in CF-PWV (as is expected from physiological principles). 19 However, none of the interventions reduced CF-PWV independently of MAP or heart rate, indicating that they do not modify the material properties of the aortic wall. It remains to be determined whether greater WL and more prolonged periods of CPAP therapy exert favorable effects on large artery stiffness.
Our study should be interpreted in the context of its strengths and limitations. Strengths of our study include its prospective randomized experimental design, the assessment of central hemodynamics with high-fidelity carotid tonometry, and the design to assess the effects of WL, CPAP, and their combination, thus separating the effect of CPAP versus OSA treatment on the study end points. There are also limitations to our study. The study was not blinded for treatment assignment or outcome assessment. We did not include a sham CPAP or placebo control group; however, both sham CPAP and absence of CPAP therapy are accepted as adequate controls for an active CPAP intervention. 37 We did not assess ambulatory BP and included a nondiabetic population with significant obesity and moderate-to-severe OSA. Our results are therefore not necessarily generalizable to patients with milder OSA, milder obesity, or those with diabetes mellitus. The magnitude of BP reduction in the monotherapy arms was relatively small. Although it is possible that this was partially because of the inclusion of both hypertensive and normotensive participants in the study, the mean magnitude of BP reduction with CPAP observed in our study is comparable to the BP reduction seen in previous trials with CPAP in hypertensive populations. 32, 38 We performed single, rather than duplicate arterial tonometry measurements at each visit. Despite the randomized nature of the study, we encountered imbalances in baseline characteristics which may have influenced the results. Furthermore, this analysis represented a subsample of the parent trial, with a lower representation of Black participants.
Perspectives
Our study provides evidence that both OSA and obesity have independent causal relationship with elevated central SBP and that among obese subjects with OSA, combination therapy with WL and CPAP is effective in reducing central systolic pressure. However, this effect is largely mediated by changes in mean, rather than central pulse pressure. WL and CPAP, alone or in combination, did not reduce large artery stiffness in this population. Our study adds support to the concept that in obese patients with OSA, combination therapy with CPAP and WL is required to address the increased cardiovascular risk factor burden of this population.
